Paul J. Hastings, President and Chief Executive Officer

Mr. Hastings brings more than 20 years of experience as a biotechnology and pharmaceutical industry executive. From 2002 to 2005, he was President and Chief Executive Officer of QLT, Inc., where he managed the ongoing development and commercialization alliance with Novartis of QLT's anti-blindness photodynamic therapy treatment generating approximately $500 million in annual sales. He also led QLT in the successful acquisitions of Kinetek and Atrix, which significantly expanded top-line sales and revenues, as well as internal development and discovery capabilities. Prior to QLT, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, a fully integrated publicly traded drug discovery and development organization that specialized in target-specific collaborations with multinational pharmaceutical companies. Axys was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation, a publicly traded biopharmaceuticals company, where he was responsible for worldwide commercial operations of Chiron's biopharma business. Prior he was President and Chief Executive officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation including serving as President of Genzyme Therapeutics, Europe as well as President of Worldwide Therapeutics. Mr. Hastings also served as Vice President Marketing and Sales, and General Manager, Europe, for Synergen Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche. Mr. Hastings serves on the board of directors of ViaCell Inc, Cerimon Pharmaceuticals, and serves as a director on the boards of the Biotechnology Industry Association and BayBIO. He received a Bachelor of Science degree in pharmacy from the University of Rhode Island.